» Articles » PMID: 24692290

Administration of 3,5-diiodothyronine (3,5-T2) Causes Central Hypothyroidism and Stimulates Thyroid-sensitive Tissues

Abstract

In general, 3,5-diiodothyronine (3,5-T2) increases the resting metabolic rate and oxygen consumption, exerting short-term beneficial metabolic effects on rats subjected to a high-fat diet. Our aim was to evaluate the effects of chronic 3,5-T2 administration on the hypothalamus-pituitary-thyroid axis, body mass gain, adipose tissue mass, and body oxygen consumption in Wistar rats from 3 to 6 months of age. The rats were treated daily with 3,5-T2 (25, 50, or 75 μg/100 g body weight, s.c.) for 90 days between the ages of 3 and 6 months. The administration of 3,5-T2 suppressed thyroid function, reducing not only thyroid iodide uptake but also thyroperoxidase, NADPH oxidase 4 (NOX4), and thyroid type 1 iodothyronine deiodinase (D1 (DIO1)) activities and expression levels, whereas the expression of the TSH receptor and dual oxidase (DUOX) were increased. Serum TSH, 3,3',5-triiodothyronine, and thyroxine were reduced in a 3,5-T2 dose-dependent manner, whereas oxygen consumption increased in these animals, indicating the direct action of 3,5-T2 on this physiological variable. Type 2 deiodinase activity increased in both the hypothalamus and the pituitary, and D1 activities in the liver and kidney were also increased in groups treated with 3,5-T2. Moreover, after 3 months of 3,5-T2 administration, body mass and retroperitoneal fat pad mass were significantly reduced, whereas the heart rate and mass were unchanged. Thus, 3,5-T2 acts as a direct stimulator of energy expenditure and reduces body mass gain; however, TSH suppression may develop secondary to 3,5-T2 administration.

Citing Articles

Comparative effects of 3,5-diiodo-L-thyronine and 3,5,3'-triiodo-L-thyronine on mitochondrial damage and cGAS/STING-driven inflammation in liver of hypothyroid rats.

Giacco A, Petito G, Silvestri E, Scopigno N, Vigliotti M, Mercurio G Front Endocrinol (Lausanne). 2024; 15:1432819.

PMID: 39301315 PMC: 11410700. DOI: 10.3389/fendo.2024.1432819.


Adipose Tissue Remodeling in Obesity: An Overview of the Actions of Thyroid Hormones and Their Derivatives.

Petito G, Cioffi F, Magnacca N, de Lange P, Senese R, Lanni A Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111329 PMC: 10146771. DOI: 10.3390/ph16040572.


Extranuclear effects of thyroid hormones and analogs during development: An old mechanism with emerging roles.

Incerpi S, Gionfra F, De Luca R, Candelotti E, De Vito P, Percario Z Front Endocrinol (Lausanne). 2022; 13:961744.

PMID: 36213288 PMC: 9540375. DOI: 10.3389/fendo.2022.961744.


3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?.

Sane R, Wirth E, Kohrle J Metabolites. 2022; 12(7).

PMID: 35888706 PMC: 9322486. DOI: 10.3390/metabo12070582.


3,5-Diiodo-L-Thyronine (T2) Administration Affects Visceral Adipose Tissue Inflammatory State in Rats Receiving Long-Lasting High-Fat Diet.

Petito G, Cioffi F, Silvestri E, De Matteis R, Lattanzi D, de Lange P Front Endocrinol (Lausanne). 2021; 12:703170.

PMID: 34322094 PMC: 8312549. DOI: 10.3389/fendo.2021.703170.


References
1.
Horst C, Harneit A, Seitz H, Rokos H . 3,5-Di-iodo-L-thyronine suppresses TSH in rats in vivo and in rat pituitary fragments in vitro. J Endocrinol. 1995; 145(2):291-7. DOI: 10.1677/joe.0.1450291. View

2.
Lanni A, Moreno M, Cioffi M, Goglia F . Effect of 3,3'-di-iodothyronine and 3,5-di-iodothyronine on rat liver mitochondria. J Endocrinol. 1993; 136(1):59-64. DOI: 10.1677/joe.0.1360059. View

3.
Moreno M, Silvestri E, De Matteis R, de Lange P, Lombardi A, Glinni D . 3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. FASEB J. 2011; 25(10):3312-24. DOI: 10.1096/fj.11-181982. View

4.
Mollica M, Lionetti L, Moreno M, Lombardi A, de Lange P, Antonelli A . 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol. 2009; 51(2):363-70. DOI: 10.1016/j.jhep.2009.03.023. View

5.
Garcia-G C, Lopez-Bojorquez L, Nunez J, Valverde-R C, Orozco A . 3,5-Diiodothyronine in vivo maintains euthyroidal expression of type 2 iodothyronine deiodinase, growth hormone, and thyroid hormone receptor beta1 in the killifish. Am J Physiol Regul Integr Comp Physiol. 2007; 293(2):R877-83. DOI: 10.1152/ajpregu.00101.2007. View